GRI Bio, Inc. (NASDAQ: GRI) to Participate in the Virtual Investor Summer Spotlight Series
July 05 2023 - 7:45AM
GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a
biotechnology company advancing an innovative pipeline of Natural
Killer T (“NKT”) cell modulators for the treatment of inflammatory,
fibrotic and autoimmune diseases, today announced that Marc Hertz,
Ph.D., President and Chief Executive Officer, Albert Agro, Ph.D.,
Chief Medical Officer and Vipin Kumar, Ph.D., Chief Scientific
Officer of GRI Bio will participate in the Virtual Investor Summer
Spotlight Series on Tuesday, July 11, 2023 at 2:00 PM ET.
A live video webcast of the presentation will be
available on the Events page of the Investors section of the
Company’s website (www.gribio.com). A webcast replay will be
available approximately two hours following the live presentation
and will remain accessible for 90 days.About GRI Bio,
Inc.
GRI Bio is a clinical-stage biopharmaceutical
company focused on fundamentally changing the way inflammatory,
fibrotic and autoimmune diseases are treated. GRI Bio’s therapies
are designed to target the activity of NKT cells, which are key
regulators earlier in the inflammatory cascade, to interrupt
disease progression and restore the immune system to homeostasis.
NKT cells are innate-like T cells that share properties of both NK
and T cells and are a functional link between the innate and
adaptive immune responses. Type I invariant NKT (“iNKT”) cells play
a critical role in propagating the injury, inflammatory response,
and fibrosis observed in inflammatory and fibrotic indications. GRI
Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity
and is being developed as a novel oral therapeutic for the
treatment of idiopathic pulmonary fibrosis, a serious disease with
significant unmet need. The Company is also developing a pipeline
of novel type 2 NKT agonists for the treatment of systemic lupus
erythematosus. Additionally, with a library of over 500 proprietary
compounds, GRI Bio has the ability to fuel a growing pipeline.
Forward Looking Statements
This press release contains “forward-looking
statements” within the meaning of the “safe harbor” provisions of
the Private Securities Litigation Reform Act of 1995.
Forward-looking statements may be identified by the use of words
such as “anticipate,” “believe,” “contemplate,” “could,”
“estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,”
“potential,” “predict,” “project,” “target,” “aim,” “should,”
“will,” “would,” or the negative of these words or other similar
expressions. These forward-looking statements are based on the
Company’s current beliefs and expectations. Forward-looking
statements include, but are not limited to, statements regarding:
the Company’s expectations with respect to development and
commercialization of the Company’s product candidates, the
initiation or completion of clinical trials, the potential benefits
and impact of the Company’s product candidates, and any estimate or
implication as to potential market size or potential revenue.
Actual results may differ from the forward-looking statements
expressed by the Company in this press release and consequently,
you should not rely on these forward-looking statements as
predictions of future events. These forward-looking statements are
subject to inherent uncertainties, risks and assumptions that are
difficult to predict, including, without limitation: (1) the
inability to maintain the listing of the Company’s common stock on
Nasdaq; (2) changes in applicable laws or regulations; (3) the
inability of the Company to raise financing in the future; (4) the
success, cost and timing of the Company’s product development
activities; (5) the inability of the Company to obtain and maintain
regulatory clearance or approval for their products, and any
related restrictions and limitations of any cleared or approved
product; (6) the inability of the Company to identify, in-license
or acquire additional technology; (7) the inability of the Company
to compete with other companies currently marketing or engaged in
the development of products and services that the Company is
currently developing; (8) the size and growth potential of the
markets for the Company’s products and services, and its ability to
serve those markets, either alone or in partnership with others;
(9) inaccuracy in the Company’s estimates regarding expenses,
future revenue, capital requirements and needs for and the ability
to obtain additional financing; (10) the Company’s ability to
protect and enforce its intellectual property portfolio, including
any newly issued patents; and (10) other risks and uncertainties
indicated from time to time in the Company’s filings with the U.S.
Securities and Exchange Commission (the “SEC”), including the risks
and uncertainties described in the “Risk Factors” section of the
Company’s most recent Annual Report on Form 10-K filed with the SEC
on February 24, 2023 and Quarterly Report on Form 10-Q filed with
the SEC on May 15, 2023 and subsequently filed reports.
Forward-looking statements contained in this announcement are made
as of this date, and the Company undertakes no duty to update such
information except as required under applicable law. This press
release also contains estimates and other statistical data made by
independent parties and by the Company relating to market size and
growth and other data about its industry. This data involves a
number of assumptions and limitations, and you are cautioned not to
give undue weight to such estimates.
Investor Contact:JTC Team,
LLCJenene Thomas(833) 475-8247GRI@jtcir.com
GRI Bio (NASDAQ:GRI)
Historical Stock Chart
From May 2024 to Jun 2024
GRI Bio (NASDAQ:GRI)
Historical Stock Chart
From Jun 2023 to Jun 2024